ABX464 Phase 2a ulcerative colitis maintenance study showed excellent longterm efficacy and continued safetyABX464 Phase 2b ulcerative colitis study progressing well in 15 European countries and Canada with patient enrollment on targetFDA granted ABX464 IN...
↧